The findings of a single-arm cohort study involving 42 patients with refractory and/or relapsed B-cell lymphoblastic leukaemia (B-ALL) indicate that low-dose (1 × 105/kg) chimeric antigen receptor (CAR) T cells are safe and effective in this setting. 90% of patients entered complete remission, or complete remission with an incomplete count recovery, with only mild, or mild-to-moderate cytokine-release syndrome reported in most patients. These findings indicate a need for comparative studies designed to explore the efficacy of this approach.
References
Pan, J. et al. High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients. Leukemia http://dx.doi.org/10.1038/leu.2017.145 (2017)
Rights and permissions
About this article
Cite this article
Sidaway, P. Low-dose CAR T cells are safe and effective. Nat Rev Clin Oncol 14, 524 (2017). https://doi.org/10.1038/nrclinonc.2017.107
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2017.107